What is claimed is:

1. A compound of formula I



(I)

or a stereoisomeric form of a compound of the formula I or a physiologically tolerable salt of a compound of the formula I,

where B_6, B_7, B_8 and B_9 are ring atoms independently chosen from carbon atoms and nitrogen atoms, where B_6, B_7, B_8 and B_9 together comprise no more than two nitrogen atoms; wherein

in case a)

the substituents R^1, R^2 and R^3 may be independently chosen from:

1.1. hydrogen atom,

1.2. halogen,

1.3. -CN,

1.4. -COOH,

1.5. $-NO_2$,

1.6. $-NH_2$,

1.7. $-O-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from:

1.7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or $-O-(C_1-C_4)$-alkyl,

1.7.2 halogen,

1.7.3 $-NH_2$,

1.7.4 -OH,

1.7.5 $-COOR^{16}$, wherein R^{16} is hydrogen atom or $-(C_1-C_{10})$-alkyl,

1.7.6 $-NO_2$,

1.7.7 $-S(O)_y-R^{14}$, wherein y is zero, 1 or 2, R^{14} is $-(C_1-C_{10})$-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those defined under 1.7.1 to 1.7.11, amino or $-N(R^{13})_2$,
wherein R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$-alkyl, $-C(O)-(C_1-C_7)$-alkyl, -C(O)-phenyl, $-C(O)-NH-(C_1-C_7)$-alkyl, -C(O)-O-phenyl, -C(O)-NH-phenyl, $-C(O)-O-(C_1-C_7)$-alkyl, $-S(O)_y-R^{14}$, wherein R^{14} and y are as defined in 1.7.7,
and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or
R^{13} together with the nitrogen atom to which it is bonded may be independently chosen to form a heterocycle having 5 to 7 ring atoms,

1.7.8 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted independently of one another as defined under 1.7.1 to 1.7.11,

1.7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,

1.7.10 $-(C_3-C_7)$-cycloalkyl or

1.7.11 =O,

1.8. $-N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7 above,

1.9. $-NH-C(O)-R^{15}$, wherein R^{15} is

1.9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan,

imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by $-CF_3$, by benzyl or by $-(C_1-C_{10})$-alkyl, wherein the $-(C_1-C_{10})$-alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

1.9.2 $-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above or by $-O-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

1.9.3 $-(C_3-C_7)$-cycloalkyl,

1.9.4 $-N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7 above, or

1.9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by $-O-(C_1-C_{10})$-alkyl, by –CN, by $-CF_3$, by $-(C_1-C_{10})$-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or by two substituents of said phenyl which form a dioxolan ring ,

1.10. $-S(O)_y-R^{14}$, wherein R^{14} and y are as defined in 1.7.7 above,

1.11. $-C(O)-R^{12}$, wherein R^{12} is phenyl or $-(C_1-C_7)$-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

1.12. $-C(O)-O-R^{12}$, wherein R^{12} is as defined in 1.11. above,

1.13. -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

1.14. -O-(C_1-C_6)-alkyl-O-(C_1-C_6)-alkyl,

1.15. -O-(C_0-C_4)-alkyl-(C_3-C_7)-cycloalkyl,

1.16. -(C_1-C_4)-alkyl-N(R^{13})$_2$, wherein R^{13} is as defined in 1.7.7 above

1.17. -CF_3 or

1.18. -CF_2-CF_3,

R^4 is 1. -(C_1-C_{10})-alkyl, wherein alkyl is mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

2. -CF_3 ,

3. -CF_2-CF_3,

4. -CN,

5. -S(O)y-R^{14} , wherein R^{14} and y are as defined in 1.7.7 above,

6. -NH_2,

7. -O-(C_1-C_{10})-alkyl, wherein alkyl is mono- to penta- substituted by substituents independently chosen from

7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or –O-(C_1-C_4)-alkyl,

7.2 halogen,

7.3 -NH_2,

7.4 -OH,

7.5 -$COOR^{16}$, wherein R^{16} is hydrogen atom or -(C_1-C_{10})-alkyl,

7.6 -NO_2,

7.7 -$S(O)_y$-R^{14} , wherein y is zero, 1 or 2, R^{14} is -(C_1-C_{10})-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or -N(R^{13})$_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, phenyl, -(C_1-C_{10})-alkyl, -C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, -C(O)-NH-(C_1-C_7)-alkyl, -C(O)-O-phenyl, -C(O)-NH-phenyl, -C(O)-O-(C_1-C_7)-alkyl, -$S(O)_y$-R^{14}, wherein R^{14} and y are defined as in 7.7 above,
and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or

R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

7.8 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, thiophene, 2-isoxazoline, isothiazolidine, 2-isothiazoline, or thiomorpholine,

7.10 -(C_3-C_7)-cycloalkyl or

7.11 =O,

8. -$N(R^{17})_2$, wherein R^{17} is independently of one another chosen from hydrogen atom, phenyl, -(C_1-C_{10})-alkyl, -C(O)-phenyl, -C(O)-NH-(C_1-C_7)-alkyl, -C(O)-(C_1-C_{10})-alkyl, -C(O)-O-phenyl, -C(O)-NH-phenyl, -C(O)-O-(C_1-C_7)-alkyl, -$S(O)_y$-R^{14}, wherein R^{14} and y are as defined as in 7.7 above,
and wherein alkyl or phenyl in each case are unsubstituted or mono- to penta- substituted independently of one another as defined under 1.7.1 to 1.7.11 above, or

R^{17} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

9. -NH-C(O)-R^{15}, wherein R^{15} is

9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, -CF_3, benzyl or by -(C_1-C_{10})-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

9.2 -(C_1-C_{10})-alkyl, wherein alkyl is mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above or by -O-(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

9.3 -(C_3-C_7)-cycloalkyl,

9.4 -N(R^{13})$_2$, wherein R^{13} is as defined in 1.7.7 above provided that
-N(R^{13})$_2$ is not -NH_2, or

9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by -O-(C_1-C_{10})-alkyl, by –CN, by -CF_3, by -(C_1-C_{10})-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or by two substituents of the phenyl radical which form a dioxolan ring

,

10. $-C(O)-R^{12}$, wherein R^{12} is phenyl or $-(C_1-C_7)$-alkyl, wherein phenyl or alkyl are mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

11. $-C(O)-O-R^{12}$, wherein R^{12} is phenyl or $-(C_1-C_7)$-alkyl, wherein phenyl or alkyl are mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

12. $-O-(C_1-C_6)$-alkyl-$O-(C_1-C_6)$-alkyl,

13. $-O-(C_0-C_4)$-alkyl-(C_3-C_7)-cycloalkyl or

14. $-(C_1-C_4)$-alkyl-$N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7 above,

R^5 is

1. a hydrogen atom,

2. $-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.4 above,

3. $-C(O)-R^9$, wherein R^9 is

   $-NH_2$, $-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.4, or $-N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7 above, or

4. $-S(O)_2-R^9$, wherein R^9 is as defined in 3 above, or

R^4 and R^5 together with the atom to which they are bonded form a heterocycle, or

R^3 and R^5 together with the atom to which they are bonded form a heterocycle containing an additional oxygen atom in the ring and

R^6, R^7 and R^8 independently of one another are chosen from hydrogen atom or methyl, or

in case b)

the substituents R^1, R^2 and R^4 may be independently chosen as defined under 1.1 to 1.18 in case a) above,

R^3 is 1. $-CF_3$,

2. $-CF_2-CF_3$,

3. -CN,

4. -COOH,

5. $-NO_2$,

6. $-NH_2$,

7. $-O-(C_1-C_{10})$-alkyl, wherein alkyl is mono- to penta substituted by substituents independently chosen from

7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or –O-(C_1-C_4)-alkyl,

7.2 halogen,

7.3 $-NH_2$,

7.4 -OH,

7.5 $-COOR^{16}$, wherein R^{16} is hydrogen atom or $-(C_1-C_{10})$-alkyl,

7.6 $-NO_2$,

7.7 $-S(O)_y-R^{14}$, wherein y is zero, 1 or 2, R^{14} is $-(C_1-C_{10})$-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or $-N(R^{13})_2$, wherein R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$-alkyl, $-C(O)-(C_1-C_7)$-alkyl, -C(O)-phenyl, $-C(O)-NH-(C_1-C_7)$-alkyl, -C(O)-O-phenyl, -C(O)-NH-phenyl, $-C(O)-O-(C_1-C_7)$-alkyl, $-S(O)_y-R^{14}$, wherein R^{14} and y are defined as in 7.7 above,
and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or
R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

7.8 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta- by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,

7.10 -(C_3-C_7)-cycloalkyl or

7.11 =O,

8. -$N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7 above,

9. -NH-C(O)-R^{15}, wherein R^{15} is

9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine, wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, -CF_3, benzyl or by -(C_1-C_{10})-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

9.2 -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above or by -O-(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

9.3 -(C_3-C_7)-cycloalkyl,

9.4 -$N(R^{13})_2$, wherein R^{13} is as defined in 1.7.7 above, or

9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, by -O-(C_1-C_{10})-alkyl, by –CN, by -CF_3, by -(C_1-C_{10})-alkyl, wherein alkyl is mono to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above, or by two substituents of the phenyl radical which form a dioxolan ring,

10. -S(O)y-R^{14} , wherein R^{14} and y are as defined in 1.7.7 above,

11. -C(O)-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

12. -C(O)-O-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

13. -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

14. -O-(C_1-C_6)-alkyl-O-(C_1-C_6)-alkyl,

15. -O-(C_0-C_4)-alkyl-(C_3-C_7)-cycloalkyl or

16. -(C_1-C_4)-alkyl-N(R^{13})$_2$, wherein R^{13} is as defined in 1.7.7 above,

R^5 is as defined as R^5 in case a) above,

R^6, R^7 and R^8 independently of one another are chosen from hydrogen atom or methyl.

2. A compound of the formula I as claimed in claim 1, wherein in case a)

B_6, B_7, B_8, and B_9 are each a carbon atom,

R^1, R^2 and R^3 independently of one another are chosen from hydrogen atom, halogen, cyano, nitro, amino, -O-(C_1-C_7)-alkyl, wherein alkyl is unsubstituted or substituted by phenyl,-CF_2-CF_3, -CF_3, -N(R^{18})$_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein alkyl, pyridyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

$S(O)_y$-R^{14},

wherein y is zero, 1 or 2, and R^{14} is -(C_1-C_{10})-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or -N(R^{18})$_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein each alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, or

-C(O)-O-R^{12}, wherein R^{12} is as defined as in 1.11 above,

R^4 is cyano, amino, -O-(C_1-C_7)-alkyl, wherein alkyl is substituted by phenyl; -CF_2-CF_3, -CF_3, -N(R^{18})$_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein each alkyl, pyridyl or phenyl are unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

$S(O)_y$-R^{14},

wherein y is zero, 1 or 2, and R^{14} is -(C_1-C_{10})-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or -$N(R^{18})_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein each alkyl is unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, or

-C(O)-O-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein said phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

R^6, R^7 and R^8 independently of one another are chosen from hydrogen atom or methyl, and

R^5 is as defined as for case a) above.

3 A compound of the formula I as claimed in claim 1,

wherein in case b)

the substituents R^1, R^2 and R^4 independently of one another are hydrogen atom, halogen, cyano, nitro, amino, -O-(C_1-C_7)-alkyl, wherein alkyl is unsubstituted or substituted by phenyl,

-CF_2-CF_3, -CF_3, -$N(R^{18})_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-

alkyl, wherein each alkyl, pyridyl or phenyl are unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

$S(O)_y$-R^{14},

wherein y is zero, 1 or 2, and R^{14} is -(C_1-C_{10})-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or -$N(R^{18})_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein each alkyl is unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, or

-C(O)-O-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein said phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

R^3 is cyano, nitro, amino, -O-(C_1-C_7)-alkyl, wherein alkyl is substituted by phenyl,-CF_2-CF_3, -CF_3, -$N(R^{18})_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein each alkyl, pyridyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R^{18} together with the

nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

$S(O)_y$-R^{14},

wherein y is zero, 1 or 2, and R^{14} is -(C_1-C_{10})-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, amino or -$N(R^{18})_2$,

wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -C(O)-(C_1-C_7)-alkyl, wherein each alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11, or R^{18} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, or

-C(O)-O-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein said phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 above,

R^6, R^7 and R^8 independently of one another are chosen from hydrogen atom or methyl, and

R^5 is as defined in claim 1.

4. A compound of formula II



(II)

or a stereoisomeric form of a compound of the formula II or a physiologically tolerable salt of a compound of the formula II, wherein;

R^1 and R^2 are independently of one another chosen from hydrogen atom, halogen, cyano, amino, -O-(C_1-C_4)-alkyl, nitro, -CF_3, -CF_2-CF_3, -$S(O)_y$-R^{14},

wherein y is 1 or 2, R^{14} is amino, -(C_1-C_7)-alkyl or phenyl, which phenyl is unsubstituted or mono- to tri-substituted as defined for substituents under 1.7.1 to 1.7.11 in claim 1,

-$N(R^{18})_2$, wherein R^{18} is independently of one another chosen from hydrogen atom,-(C_1-C_7)-alkyl-C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, C(O)-pyridyl, -C(O)-NH-(C_1-C_4)-alkyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -(C_1-C_{10})-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.11 in claim 1, or R^{18} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

R^3 is cyano, amino, -O-(C_1-C_4)-alkyl, nitro, -CF_3, -CF_2-CF_3, -$S(O)_y$-R^{14}, wherein y is 1 or 2, R^{14} is amino, -(C_1-C_7)-alkyl or phenyl, which phenyl is unsubstituted or mono- to tri- substituted as defined for substituents under 1.7.1 to 1.7.11 in claim 1,

-$N(R^{18})_2$, wherein R^{18} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl-C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-O-phenyl, -C(O)-NH-(C_1-C_4)-alkyl, -C(O)-O-(C_1-C_4)-alkyl or -(C_1-C_{10})-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.11 in claim 1, or R^{18} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, and

R^5 is hydrogen atom, -(C_1-C_{10})-alkyl,

wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 1.7.1 to 1.7.4 in claim 1,

$-C(O)-R^9$ or $-S(O)_2-R^9$, wherein

R^9 is $-(C_1-C_{10})$-alkyl, $-O-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 to 1.7.4 in claim 1, or

phenyl, which is unsubstituted or mono- to tri- substituted as defined under 1.7.1 to 1.7.11 in claim 1, or $-N(R^{18})_2$, wherein R^{18} is independently of one another chosen from hydrogen atom,$-(C_1-C_7)$-alkyl-C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, C(O)-pyridyl, -C(O)-NH-(C_1-C_4)-alkyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or $-(C_1-C_{10})$-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted independently of one another as defined under 1.7.1 in to 1.7.11 in claim 1, or R^{18} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.

5. A compound of formula II as claimed in claim 4, wherein

R^1 is bromo, $-CF_3$ or chloro,

R^2 is hydrogen atom or $O-(C_1-C_2)$-alkyl,

R^3 is $-N(R^{18})_2$, wherein R^{18} is independently of one another chosen from hydrogen atom, -N-C(O)-pyridyl, -C(O)-phenyl, $-(C_1-C_7)$-alkyl, -C(O)-(C_1-C_4)-alkyl or -C(O)-O-(C_1-C_4)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from halogen or $-O-(C_1-C_2)$-alkyl, and

R^5 is hydrogen atom, methyl or $-S(O)_2-CH_3$.

6. A compound of the formula II as claimed in claim 4, wherein

R^1 is chloro, R^3 is $-N-C(O)-CH_2-O-CH_3$ and R^2 and R^5 are each hydrogen atom, or

R^1 is chloro, R^3 is -N-C(O)-pyridyl, wherein pyridyl is unsubstituted or substituted by chloro, R^2 is hydrogen atom or $-O-CH_3$ and R^5 is hydrogen atom, or

R^1 is chloro, R^3 is -N-C(O)-phenyl, wherein phenyl is mono- or di-substituted by fluoro and R^2 and R^5 are each hydrogen atom.

7. A process for the preparation of a compound of the formula I as claimed in claim 1, which comprises

reacting a compound of formula III



(III)

in which R^1, R^2, R^3, R^4, B_6, B_7, B_8 and B_9 are each as defined in formula I, with a compound of the formula IV,



(IV)

in the presence of a acid, to yield a compound of the formula V



(V)

which is reacted with hydrazine hydrate and later with R^6CHO or formaldehyde (R^6 is H) to give a compound of formula VI



(VI)

and then oxidizing formula VI to give a compound of the formula VII,



(VII)

where R^1 to R^4, R^6 to R^8 and B_6 to B_9 are as defined in formula I, a compound of formula (I).

8. A process according to claim 7, wherein a compound of the formula VII is reacted with a compound of the formula VIII

$$Y\text{-}R^5 \quad \text{(VIII)}$$

where Y is halogen or –OH and R^5 is as defined in formula I, to give a compound of the formula I.

9. A process according to claim 7, which further comprises resolving a compound of the formula I formed by the process of claim 7, which on account of its chemical structure occurs in enantiomeric forms, into the

pure enantiomers by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure compounds such as amino acids, separation of the diastereomers thus obtained, and removal of the chiral auxiliary groups.

10. A process according to claim 8, which further comprises resolving a compound of the formula I formed by the process of claim 8, which on account of its chemical structure occurs in enantiomeric forms, into the pure enantiomers by salt formation with enantiomerically pure acids or bases, chromatography on chiral stationary phases or derivatization by means of chiral enantiomerically pure compounds such as amino acids, separation of the diastereomers thus obtained, and removal of the chiral auxiliary groups.

11. A process according to claim 7, which further comprises isolating a compound of the formula I prepared by the process of claim 7, either in free form or, in the case of the presence of acidic or basic groups, converting it into physiologically tolerable salts.

12. A process according to claim 8, which further comprises isolating a compound of the formula I prepared by the process of claim 8, either in free form or, in the case of the presence of acidic or basic groups, converting it into physiologically tolerable salts.

13. A process according to claim 9, which further comprises isolating a compound of the formula I prepared by process 9, either in free form or, in the case of the presence of acidic or basic groups, converting it into physiologically tolerable salts.

14. A composition which comprises an efficacious amount of at least one compound chosen from the compounds of formula I as claimed in claim 1, a physiologically tolerable salt of the compounds of the formula I or an optionally stereoisomeric form of the compounds of the formula I, together with at least one pharmaceutically suitable and physiologically tolerable excipient, additive, active compound or auxiliary.

15. A method for the production of a compound for the prophylaxis or therapy of disorders in whose course an increased activity of I_KB kinase is involved, comprising

bringing into a suitable administration form at least one compound chosen from a compound of formula I,



(I)

a stereoisomeric form of a compound of formula I or a physiologically tolerable salt of a compound of formula I,

wherein B_6, B_7, B_8 and B_9 are ring atoms independently chosen from carbon atoms and nitrogen atoms and wherein B_6, B_7, B_8 and B_9 together are no more than two nitrogen atoms at the same time;

where the substituents R^1, R^2, R^3, R^4 and R^8 may be independently chosen from

1. hydrogen atom,
2. halogen,
3. -OH,
4. -CN,
5. sulfo,
6. $-NO_2$,

7. $-NH_2$,
8. alkoxy,
9. substituted amino,
10. $-NH-C(O)-R^{15}$, wherein R^{15} is a heterocycle having 5 to 7 ring atoms, an alkyl, an aryl, a substituted aryl or a substituted alkyl,
11. -COOH,
12. $-O-R^{10}$, wherein R^{10} is alkyl, substituted alkyl or aryl,
13. $-C(O)-R^{12}$, wherein R^{12} is alkyl, substituted alkyl or aryl,
14. $-C(O)-O-R^{12}$, wherein R^{12} is alkyl, substituted alkyl or aryl,
15. aryl,
16. -O-aryl,
17. substituted aryl,
18. –O-substituted aryl,
19. alkyl,
20. substituted alkyl,
21. $-CF_3$ or
22. $-CF_2-CF_3$,

provided that at least one of R^1, R^2, R^3, R^4 and R^8 is not a hydrogen atom,

R^5 is
1. hydrogen atom,
2. alkyl,
3. alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
4. $-C(O)-R^9$ or
5. $-S(O)_2-R^9$, in which

R^9 is
a) alkyl,
b) alkyl radical, substituted at one or more positions by one or more of the radicals, halogen, amino or hydroxyl,
c) aryl,

d) aryl radical, substituted at one or more positions by one or more of the radicals, halogen, amino, or hydroxyl,

e) $-NH_2$,

f) alkoxy or

g) substituted amino, and

R^6 and R^7 may be independently chosen from

1. hydrogen atom,
2. halogen,
3. -OH,
4. methyl,
5. $-O-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to tri-substituted by substituents independently chosen from
   - 5.1 aryl,
   - 5.2 halogen,
   - 5.3 $-NO_2$,
   - 5.4 sulfo,
   - 5.5 -COOH,
   - 5.6 $-NH_2$,
   - 5.7 $-O-(C_1-C_4)$-alkyl or
   - 5.8 -OH, or
6. $-N(R^{13})_2$, wherein R^{13} is independently of one another chosen from hydrogen atom, aryl, $-C(O)-(C_1-C_4)$-alkyl or substituted aryl or alkyl, wherein said $-C(O)-(C_1-C_4)$-alkyl is unsubstituted or mono- to tri-substituted independently of one another as defined under 5.1 to 5.8, or

   R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.

16. The method as claimed in claim 15, wherein

B_6, B_7, B_8, and B_9 are each a carbon atom,

R^1, R^2, R^3, R^4 and R^8 are independently chosen from

1. hydrogen atom,
2. halogen,
3. -CN,
4. -COOH,
5. $-NO_2$,
6. $-NH_2$,
7. $-O-(C_1-C_{10})$-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from
   - 7.1 phenyl, which is unsubstituted or mono- to penta- substituted by substituents independently chosen from halogen or –O-(C_1-C_4)-alkyl,
   - 7.2 halogen,
   - 7.3 $-NH_2$,
   - 7.4 -OH,
   - 7.5 $-COOR^{16}$, wherein R^{16} is hydogen atom or $-(C_1-C_{10})$-alkyl,
   - 7.6 $-NO_2$,
   - 7.7 $-S(O)_y-R^{14}$, wherein y is zero, 1 or 2, R^{14} is $-(C_1-C_{10})$-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11, amino or $-N(R^{13})_2$, wherein R^{13} is independently of one another chosen from hydrogen atom, phenyl, $-(C_1-C_{10})$-alkyl, $-C(O)-(C_1-C_7)$-alkyl, -C(O)-phenyl, -C(O)-NH-(C_1-C_7)-alkyl, -C(O)-O-phenyl, -C(O)-NH-phenyl, $-C(O)-O-(C_1-C_7)$-alkyl, $-S(O)_y-R^{14}$, wherein R^{14} and y are as defined immediately above,
     and wherein the R^{13} alkyl or phenyl groups in each case are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, or

R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

7.8 -O-phenyl, wherein phenyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,

7.9 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,

7.10 -(C_3-C_7)-cycloalkyl or

7.11 =O,

8. -$N(R^{13})_2$, wherein R^{13} is as defined in 7.7 above,

9. -NH-C(O)-R^{15}, wherein R^{15} is

9.1 a radical selected from pyrrolidine, tetrahydropyridine, piperidine, piperazine, imidazoline, pyrazolidine, furan, morpholine, pyridine, pyridazine, pyrazine, oxolan, imidazoline, isoxazolidine, 2-isoxazoline, isothiazolidine, 2-isothiazoline, thiophene or thiomorpholine,
wherein said radical is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, -CF_3, benzyl or by -(C_1-C_{10})-alkyl, wherein alkyl is mono to tri- substituted independently of one another as defined under 7.1 to 7.11 above,

9.2 -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above or by -O-(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,

9.3 -(C_3-C_7)-cycloalkyl,

9.4 -$N(R^{13})_2$, wherein R^{13} is as defined in 7.7 above, or

9.5 phenyl, wherein phenyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, by -O-(C_1-C_{10})-alkyl, by –CN, by -CF_3, by -(C_1-C_{10})-alkyl, wherein alkyl is mono to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above, or by two substituents of the phenyl radical which form a dioxolan ring ,

10. -S(O)y-R^{14} , wherein R^{14} and y are as defined in 7.7 above,

11. -C(O)-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,

12. -C(O)-O-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,

13. -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.11 above,

14. -O-(C_1-C_6)-alkyl-O-(C_1-C_6)-alkyl,

15. -O-(C_0-C_4)-alkyl-(C_3-C_7)-cycloalkyl,

16. -(C_1-C_4)-alkyl-$N(R^{13})_2$, wherein R^{13} is as defined in 7.7 above

17. -CF_3 or

18. -CF_2-CF_3,

provided that at least one of R^1, R^2, R^3, R^4 and R^8 is not a hydrogen atom,

R^5 is 1. hydrogen atom,

2. -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta-substituted by substituents independently chosen from those as defined under 7.1 to 7.4 above,

3. -C(O)-R^9, wherein R^9 is

-NH_2, -(C_1-C_{10})-alkyl, wherein alkyl is unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.4, or -$N(R^{13})_2$, wherein R^{13} is as defined in 7.7 above, or

4. -$S(O)_2$-R^9, wherein R^9 is as defined in 3 above,

or R^4 and R^5 together with the atom to which they are bonded form a heterocycle,

or R^3 and R^5 together with the atom to which they are bonded form a heterocycle containing an additional oxygen atom in the ring and

R^6 and R^7 independently of one another are chosen from hydrogen atom or methyl.

17. The method as claimed in claim 16,

wherein

B_6, B_7, B_8, and B_9 are each a carbon atom,

R^1, R^2, R^3 and R^4 independently of one another are hydrogen atom, halogen, cyano, nitro, amino, -O-(C_1-C_7)-alkyl, phenyl, -O-phenyl, -CF_2-CF_3, -CF_3, $N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl, phenyl, -C(O)-phenyl, -C(O)-pyridyl, -C(O)-NH-phenyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl, -C(O)-(C_1-C_7)-alkyl or -(C_1-C_{10})-alkyl, wherein alkyl, pyridyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 of claim 16, or R^{13} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

-$S(O)_y$-R^{14},

wherein y is zero, 1 or 2, and R^{14} is -(C_1-C_{10})-alkyl, phenyl, which phenyl is unsubstituted or mono- to penta- substituted as defined for substituents under 7.1 to 7.11 of claim 16, amino or -$N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom,-(C_1-C_7)-alkyl-C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, C(O)-pyridyl, -C(O)-NH-(C_1-C_4)-alkyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -(C_1-C_{10})-alkyl, wherein each alkyl is unsubstituted or mono- to tri- substituted independently of one another as defined under 7.1 to 7.11 of claim 16, or R^{13} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms, or

-C(O)-O-R^{12}, wherein R^{12} is phenyl or -(C_1-C_7)-alkyl, wherein said phenyl or alkyl are unsubstituted or mono- to penta- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 of claim 16,

R^6, R^7 and R^8 independently of one another are hydrogen atom, methyl, amino, -$N(R^{13})_2$, wherein R^{13} is independently of one another chosen from hydrogen atom,-(C_1-C_7)-alkyl-C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, C(O)-pyridyl, -C(O)-NH-(C_1-C_4)-alkyl, -C(O)-O-phenyl, -C(O)-O-(C_1-C_4)-alkyl or -(C_1-C_{10})-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri- substituted independently of one another as defined under 7.1 to 7.11 of claim 16, or R^{13} together with nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,,

provided that at least one of R^1, R^2, R^3, R^4 and R^8 is not a hydrogen atom, and R^5 is as defined in claim 16.

18. A method for the production of a compound for the prophylaxis or therapy of disorders in whose course an increased activity of I_KB kinase is involved, comprising

bringing into a suitable administration form at least one compound chosen from a compound of formula II,



(II)

a stereoisomeric form of a compound of the formula II, or a physiologically tolerable salt of a compound of the formula II,

wherein, R^1, R^2 and R^3 are independently chosen from hydrogen atom, halogen, cyano, amino, -O-(C_1-C_4)-alkyl, nitro, -CF_3, -CF_2-CF_3, -$S(O)_y$-R^{14},

wherein y is 1 or 2,

R^{14} is amino, -(C_1-C_7)-alkyl, phenyl, which is unsubstituted or mono- to tri-substituted by substituents independently chosen from those as defined under 7.1 to 7.9 of claim 16, or -$N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, -(C_1-C_7)-alkyl-C(O)-(C_1-C_7)-alkyl, -C(O)-phenyl, -C(O)-O-phenyl, -C(O)-pyridyl, -C(O)-NH-(C_1-C_4)-alkyl, -C(O)-O-(C_1-C_4)-alkyl, or -(C_1-C_{10})-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri-substituted with substitutents independently chosen from those as defined under 7.1 to 7.11 of claim 16, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms,

provided that at least one of R^1, R^2 and R^3 is not a hydrogen atom, and

R^5 is hydrogen atom, -(C_1-C_{10})-alkyl,

wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.4 of claim 16, -C(O)-R^9 or -$S(O)_2$-R^9, wherein

R^9 is -(C_1-C_{10})-alkyl, -O-(C_1-C_{10})-alkyl,

wherein alkyl is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.4 of claim 16,

phenyl, which is unsubstituted or mono- to tri- substituted by substituents independently chosen from those as defined under 7.1 to 7.11 of claim 16, or -$N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, -$(C_1$-$C_7)$-alkyl-C(O)-$(C_1$-$C_7)$-alkyl, -C(O)-phenyl, -C(O)-O-phenyl, -C(O)-pyridyl, -C(O)-NH-$(C_1$-$C_4)$-alkyl, -C(O)-O-$(C_1$-$C_4)$-alkyl, or -$(C_1$-$C_{10})$-alkyl, wherein pyridyl, alkyl or phenyl are unsubstituted or mono- to tri-substituted with substitutents independently chosen from those as defined under 7.1 to 7.11 of claim 16, or R^{13} together with the nitrogen atom to which it is bonded form a heterocycle having 5 to 7 ring atoms.

19. The method as claimed in claim 18,

wherein

R^1, R^2 and R^3 are independently chosen from hydrogen atom, halogen, cyano, amino, -O-$(C_1$-$C_4)$-alkyl, nitro, -CF_3 or $N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, -$(C_1$-$C_7)$-alkyl, -C(O)-$(C_1$-$C_7)$-alkyl, -C(O)-pyridyl, -C(O)-phenyl or -C(O)-O-$(C_1$-$C_4)$-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri- substituted by substituents independently chosen from halogen or -O-$(C_1$-$C_4)$-alkyl, and

R^5 is hydrogen atom, -C(O)-CH_3-, methyl, –$S(O)_2$-CH_3, -C(O)-morpholinyl, -CH_2-CH_2-OH or -CH_2-C(O)-NH_2,

provided that no more than two of R^1, R^2, R^3 and R^5 are a hydrogen atom.

20. The method as claimed in claim 18, wherein

R^1 is bromo, -CF_3 or chloro, R^2 is hydrogen atom or O-$(C_1$-$C_2)$-alkyl, R^3 is hydrogen atom, bromo, chloro or -$N(R^{13})_2$,

wherein R^{13} is independently of one another chosen from hydrogen atom, -C(O)-phenyl, -$(C_1$-$C_7)$-alkyl, -C(O)-$(C_1$-$C_4)$-alkyl or -C(O)-O-$(C_1$-

C_4)-alkyl, wherein alkyl or phenyl are unsubstituted or mono- to tri-substituted by substituents independently chosen from halogen or -O-(C_1-C_2)-alkyl, and

R^5 is hydrogen atom, -C(O)-CH_3-, methyl or -$S(O)_2$-CH_3,

provided that no more than two of R^1, R^2, R^3 and R^5 are a hydrogen atom.

21. The method as claimed in claim 18, wherein

R^1 is chloro, R^3 is -N-C(O)-CH_2-O-CH_3 and R^2 and R^5 are each hydrogen atom, or

R^1 is chloro, R^3 is -N-C(O)-pyridyl, wherein pyridyl is unsubstituted or substituted by chloro, R^2 is hydrogen atom or –O-CH_3 and R^5 is hydrogen atom, or

R^1 is chloro, R^3 is -N-C(O)-phenyl, wherein phenyl is mono- or di-substituted by fluoro and R^2 and R^5 are each hydrogen atom, or

R^1 and R^3 are each chloro, R^2 is -C(O)-CH_3 and R^5 is hydrogen atom, or

R^1 and R^3 are each chloro, R^2 is -C(O)-CH_2-CH_3 and R^5 is hydrogen atom.

22. A method for treating a patient experiencing at least one disorder involving an increased activity of I_kB kinase, the method comprising administering to the patient an efficacious amount of at least one compound chosen from a compound of formula I as set forth in claim 1, a stereoisomeric form of a compound of the formula I, or a physiologically tolerable salt of a compound of the formula I.

23. The method as claimed in claim 22, wherein the at least one disorder is joint inflammation, acute synovitis, tuberculosis, atherosclerosis, muscle degeneration, cachexia, Reiter's syndrome, endotoxaemia, sepsis, septic shock, endotoxic shock, gram negative sepsis, gout, toxic shock syndrome, chronic pulmonary inflammatory diseases, silicosis, pulmonary sarcoidosis, bone resorption diseases, reperfusion injury, carcinoses, leukemia, sarcomas, lymph node tumors, skin carcinoses, lymphoma, apoptosis, graft versus host reaction, allograft rejection, leprosy, infections, acquired immune deficiency syndrome (AIDS); AIDS related complex; cachexia secondary to infection or malignancy; cachexia secondary to acquired immune deficiency syndrome or to cancer; keloid

and scar tissue formation; pyresis; diabetes; inflammatory bowel diseases; diseases of or injury to the brain in which over-expression of TNFα has been implicated, psoriasis, Alzheimer's disease, carcinomatous disorders (potentiation of cytotoxic therapies), cardiac infarct, chronic obstructive pulmonary disease and acute respiratory distress syndrome.

24. The method as claimed in claim 22, wherein the disorder is joint inflammation including arthritis and arthritic conditions.

25. The method as claimed in claim 24, wherein the disorder is arthritis or arthritic conditions chosen from rheumatoid arthritis, rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis, and osteoarthritis.

26. The method of claim 22, wherein the disorder is chronic pulmonary inflammatory diseases chosen from asthma and adult respiratory distress syndrome.

27. The method of claim 22, wherein the disorder is an infection chosen from viral infections, parasitic infections, and yeast and fungal infections.

28. The method of claim 27, wherein the disorder is a viral infection chosen from HIV, cytomegalovirus, influenza, adenovirus and the Herpes group of viruses.

29. The method of claim 22, wherein the disorder is malaria.

30. The method of claim 29, wherein the malaria is cerebral malaria.

31. The method of claim 22, wherein the disorder is a yeast or fungal infection including fungal meningitis; fever and myalgias due to infection.

32. The method of claim 22, wherein the the disorder is inflammatory bowel disease including Crohn's disease and ulcerative colitis.

33. The method of claim 22, wherein the the disorder is a disease of or injury to the brain including multiple sclerosis or head trauma.

34. A method for treating a patient experiencing at least one disorder, the method comprising administering to the patient an efficacious amount of at least one compound chosen from a compound of formula II as set forth in claim 4, a stereoisomeric form of a compound of the formula II, or a physiologically tolerable salt of a compound of the formula II, wherein the at least one disorder is asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, carcinomatous disorders and cardiac infarct.